
Keywords: بیماری اصلاح; ABA; abatacept; ADA; adalimumab; AIx; augmentation index; AMI; acute myocardial infarction; ANA; anakinra; Apo; apolipoprotein; AS; ankylosing spondylitis; CTZ; certolizumab pegol; CV; cardiovascular; CVD; cardiovascular disease; DMARD; disease-modifying